Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64th AASLD Liver Meeting this month in Washington, DC.

Gilead Science's tenofovir disoproxil fumarate (TDF, brand name Viread)—the currently marketed formulation—is one of the most effective antiviral drugs for hepatitis B as well as one of the most widely used antiretrovirals for HIV. TDF is generally safe and well-tolerated, but it can cause kidney toxicity in susceptible individuals and is also associated with bone loss.

Read more...

Labels: